Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.
Pingping MaoOfir CohenKailey J KowalskiJustin G KusielJorge E Buendia-BuendiaMichael S CuocoPedro ExmanSeth A WanderAdrienne G WaksUtthara NayarJon H ChungSamuel S FreemanOrit Rozenblatt-RosenVincent A MillerFrederica PiccioniDavid E RootAviv RegevEric P WinerNancy U LinNikhil WaglePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our results suggest that FGFR pathway is a distinct mechanism of acquired resistance to ER-directed therapy that can be overcome by FGFR and/or MAPK pathway inhibitors.